← Back to Clinical Trials
Recruiting NCT06498817

NCT06498817 Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06498817
Status Recruiting
Phase
Sponsor Johns Hopkins Bloomberg School of Public Health
Condition Diarrhea Infectious
Study Type INTERVENTIONAL
Enrollment 1,600 participants
Start Date 2024-08-19
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Standard RecommendationCHoBI7 Scale-Up Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,600 participants in total. It began in 2024-08-19 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The findings from previous recent randomized controlled trials of The Cholera Hospital Based Intervention for 7 Days (CHoBI7) demonstrated that this intervention was effective in significantly reducing symptomatic cholera infections, diarrheal disease, and stunting among young children in intervention households, and had significant sustained impacts on handwashing with soap behaviors and improved water quality 12 months post intervention. Therefore, the investigators next step in the transition to scale is to: (1) To tailor the CHoBI7 program for delivery in rural health facilities and market test the CHoBI7 Program to determine the feasibility of providing a modified water, sanitation, and hygiene (WASH) package with only a soapy water bottle and chlorine tablets in both urban and rural settings through formative research and engagement of key stakeholders (Formative Research Phase); and (2) To evaluate the effectiveness of delivering the CHoBI7 program in district hospitals and sub-district health complexes in rural areas in terms of increases in WASH behaviors and decreases in diarrheal disease by conducting a randomized controlled trial (RCT) (Intervention Implementation and Evaluation Phase).

Eligibility Criteria

Inclusion Criteria: * Diarrhea patients presenting with three or more loose stools over a 24h period * Having no running water inside of the patient's home * Plan to reside in current residence for the next 3 months * Have a child \<5 years in the patient's household * Have a working mobile phone in the household Exclusion Criteria: * No one will be excluded because of age, sex, religion, or sexual preference

Contact & Investigator

Central Contact

Christine Marie George, PhD

✉ cmgeorge@jhu.edu

📞 (202) 657-5798

Principal Investigator

Christine Marie George, PhD

PRINCIPAL INVESTIGATOR

Johns Hopkins Bloomberg School of Public Health

Frequently Asked Questions

Who can join the NCT06498817 clinical trial?

This trial is open to participants of all sexes, studying Diarrhea Infectious. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06498817 currently recruiting?

Yes, NCT06498817 is actively recruiting participants. Contact the research team at cmgeorge@jhu.edu for enrollment information.

Where is the NCT06498817 trial being conducted?

This trial is being conducted at Mānikganj, Bangladesh.

Who is sponsoring the NCT06498817 clinical trial?

NCT06498817 is sponsored by Johns Hopkins Bloomberg School of Public Health. The principal investigator is Christine Marie George, PhD at Johns Hopkins Bloomberg School of Public Health. The trial plans to enroll 1,600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology